Protein Folding and Aggregation in the Expanded Polyglutamine Repeat Diseases

Protein Folding Handbook

Volumn 3, Issue , 2008, Pages 1200-1244

  Wetzel, Ronald ^a  

^a NONE

Author keywords

Coding; Expansion; Genetic nature; Homopolymer; Huntington's

Indexed keywords

EID: 84889851247     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527619498.ch70     Document Type: Chapter

References (120)

1. Wilmot, G. R. & Warren, S. T. (1998). A new mutational basis for disease. In Genetic Instabilities and Hereditary Neurological Diseases (Wells, R. D. & Warren, S. T., eds.), pp. 3-12. Academic Press, San Diego.
2. Cummings, C. J. & Zoghbi, H. Y. (2000). Fourteen and counting: unraveling trinucleotide repeat diseases. Hum Mol Genet 9, 909-916.
3. Bates, G. P. & Benn, C. (2002). The polyglutamine diseases. In Huntington's Disease (Bates, G. P., Harper, P. S. & Jones, L., eds.), pp. 429-472. Oxford University Press, Oxford, U.K.
4. DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P. & Aronin, N. (1997). Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-3.
5. Ordway, J. M., Tallaksen-Greene, S., Gutekunst, C. A., Bernstein, E. M., Cearley, J. A., Wiener, H. W., Dure, L. S. t., Lindsey, R., Hersch, S. M., Jope, R. S., Albin, R. L. & Detloff, P. J. (1997). Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse [In Process Citation]. Cell 91, 753-63.
6. Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L. & Bates, G. P. (1997). Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-48.
7. Paulson, H. L., Perez, M. K., Trottier, Y., Trojanowski, J. Q., Subramony, S. H., Das, S. S., Vig, P., Mandel, J. L., Fischbeck, K. H. & Pittman, R. N. (1997). Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19, 333-44.
8. Martin, J. B. (1999). Molecular basis of the neurodegenerative disorders [published erratum appears in N Engl J Med 1999 Oct 28;341(18):1407]. N Engl J Med 340, 1970-80.
9. Chen, Y. W. (2003). Site-specific mutagenesis in a homogeneous polyglutamine tract: application to spinocerebellar ataxin-3. Protein Eng 16, 1-4.
10. Thakur, A. & Wetzel, R. (2002). Mutational analysis of the structural organization of polyglutamine aggregates. Proc Natl Acad Sci USA 99, 17014-17019.
11. Wells, R. D. & Warren, S. T. (1998). Genetic Instabilities and Hereditary Neurological Diseases, Academic Press, San Diego.
12. Bates, G. P., Harper, P. S. & Jones, L., Eds. (2002). Huntington's Disease. Oxford, U.K.: Oxford University Press.
13. Reddy, P. S. & Housman, D. E. (1997). The complex pathology of trinucleotide repeats. Curr Opin Cell Biol 9, 364-72.
14. Gusella, J. F. & MacDonald, M. E. (1998). Huntingtin: a single bait hooks many species. Curr Opin Neurobiol 8, 425-30.
15. Reddy, P. H., Williams, M. & Tagle, D. A. (1999). Recent advances in understanding the pathogenesis of Huntington's disease. Trends Neurosci 22, 248-55.
16. Lin, X., Cummings, C. J. & Zoghbi, H. Y. (1999). Expanding our understanding of polyglutamine diseases through mouse models. Neuron 24, 499-502.
17. Zoghbi, H. Y. & Orr, H. T. (1999). Polyglutamine diseases: protein cleavage and aggregation. Curr Opin Neurobiol 9, 566-70.
18. Paulson, H. L. (1999). Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold. Am J Hum Genet 64, 339-45.
19. Ferrigno, P. & Silver, P. A. (2000). Polyglutamine expansions: proteolysis, chaperones, and the dangers of promiscuity. Neuron 26, 9-12.
20. Tobin, A. J. & Signer, E. R. (2000). Huntington's disease: the challenge for cell biologists. Trends Cell Biol 10, 531-536.
21. Zoghbi, H. Y. & Orr, H. T. (2000). Glutamine repeats and neurodegeneration. Annu Rev Neurosci 23, 217-47.
22. Bates, G. (2000). Huntington's disease. In reverse gear. Nature 404, 944-5.
23. Cha, J. H. (2000). Transcriptional dysregulation in Huntington's disease. Trends Neurosci 23, 387-92.
24. McCampbell, A. & Fischbeck, K. H. (2001). Polyglutamine and CBP: fatal attraction? Nat Med 7, 528-30.
25. Ross, C. A. (2002). Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 35, 819-22.
26. Rubinsztein, D. C. (2002). Lessons from animal models of Huntington's disease. Trends Genet 18, 202-9.
27. Ross, C. A., Poirier, M. A., Wanker, E. E. & Amzel, M. (2003). Polyglutamine fibrillogenesis: the pathway unfolds. Proc Natl Acad Sci USA 100, 1-3.
28. Bates, G. (2003). Huntingtin aggregation and toxicity in Huntington's disease. Lancet 361, 1642-4.
29. Michalik, A. & Van Broeckhoven, C. (2003). Pathogenesis of polyglutamine disorders: aggregation revisited. Hum Mol Genet 12 Suppl 2, R173-86.
30. Paulson, H. (2003). Polyglutamine neurodegeneration: minding your Ps and Qs. Nat Med 9, 825-826.
31. Rudnicki, D. D. & Margolis, R. L. (2003). Repeat expansion and autosomal dominant neurodegenerative disorders: consensus and controversy. Exp. Rev. Mol. Med. 5, 1-24.
32. Koide, R., Kobayashi, S., Shimohata, T., Ikeuchi, T., Maruyama, M., Saito, M., Yamada, M., Takahashi, H. & Tsuji, S. (1999). A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? Hum Mol Genet 8, 2047-53.
33. Margolis, R. L. (2002). The spinocerebellar ataxias: order emerges from chaos. Curr Neurol Neurosci Rep 2, 447-56.
34. Albin, R. L. (2003). Dominant ataxias and Friedreich ataxia: an update. Curr Opin Neurol 16, 507-14.
35. Bowater, R. P. & Wells, R. D. (2001). The intrinsically unstable life of DNA triplet repeats associated with human hereditary disorders. Prog Nucleic Acid Res Mol Biol 66, 159-202.
36. Harper, P. S. & Jones, L. (2002). Huntington's disease: genetic and molecular studies. In Huntington's Disease (Bates, G. P., Harper, P. S. & Jones, L., eds.), pp. 113-158. Oxford University Press, Oxford, U.K.
37. Myers, R. H., Marans, K. S. & MacDonald, M. E. (1998). Huntington's Disease. In Genetic Instabilities and Hereditary Neurological Diseases (Wells, R. D. & Warren, S. T., eds.), pp. 301-323. Academic Press, San Diego.
38. Zajac, J. D. & MacLean, H. E. (1998). Kennedy's disease: clinical aspects. In Genetic Instabilities and Hereditary Neurological Diseases (Wells, R. D. & Warren, S. T., eds.), pp. 87-111. Academic Press, San Diego.
39. Cattaneo, E., Rigamonti, D., Goffredo, D., Zuccato, C., Squitieri, F. & Sipione, S. (2001). Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci 24, 182-8.
40. Kazemi-Esfarjani, P. & Benzer, S. (2000). Genetic suppression of polyglutamine toxicity in Drosophila. Science 287, 1837-40.
41. Bennett, M. J., Huey-Tubman, K. E., Herr, A. B., West, A. P., Ross, S. A. & Bjorkman, P. J. (2002). A linear lattice model for polyglutamine in CAG expansion diseases. Proc Natl Acad Sci USA 99, 11634-11639.
42. Faber, P. W., Voisine, C., King, D. C., Bates, E. A. & Hart, A. C. (2002). Glutamine/proline-rich PQE-1 proteins protect Caenorhabditis elegans neurons from huntingtin polyglutamine neurotoxicity. Proc Natl Acad Sci USA 99, 17131-6.
43. Kazantsev, A., Walker, H. A., Slepko, N., Bear, J. E., Preisinger, E., Steffan, J. S., Zhu, Y. Z., Gertler, F. B., Housman, D. E., Marsh, J. L. & Thompson, L. M. (2002). A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat Genet 25, 25.
44. Thakur, A. K., Yang, W., & Wetzel, R. (2004). Inhibition of polyglutamine aggregate cytotoxicity by a structurebased elongation inhibitor. FASEB J. 18, 923-925.
45. Yang, W., Dunlap, J. R., Andrews, R. B. & Wetzel, R. (2002). Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet 11, 2905-2917.
46. Altschuler, E. L., Hud, N. V., Mazrimas, J. A. & Rupp, B. (1997). Random coil conformation for extended polyglutamine stretches in aqueous soluble monomeric peptides. J Pept Res 50, 73-5.
47. Sharma, D., Sharma, S., Pasha, S. & Brahmachari, S. K. (1999). Peptide models for inherited neurodegenerative disorders: conformation and aggregation properties of long polyglutamine peptides with and without interruptions. FEBS Lett 456, 181-5.
48. Chen, S. & Wetzel, R. (2001). Solubilization and disaggregation of polyglutamine peptides. Protein Science 10, 887-891.
49. Chen, S., Berthelier, V., Yang, W. & Wetzel, R. (2001). Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J. Mol. Biol. 311, 173-182.
50. Masino, L., Kelly, G., Leonard, K., Trottier, Y. & Pastore, A. (2002). Solution structure of polyglutamine tracts in GST-polyglutamine fusion proteins. FEBS Lett 513, 267-72.
51. Shi, Z., Olson, C. A., Rose, G. D., Baldwin, R. L. & Kallenbach, N. R. (2002). Polyproline II structure in a sequence of seven alanine residues. Proc Natl Acad Sci USA 99, 9190-5.
52. Rucker, A. L., Pager, C. T., Campbell, M. N., Qualls, J. E. & Creamer, T. P. (2003). Host-guest scale of left-handed polyproline II helix formation. Proteins 53, 68-75.
53. Perutz, M. F., Johnson, T., Suzuki, M. & Finch, J. T. (1994). Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci USA 91, 5355-8.
54. Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, G. P., Davies, S. W., Lehrach, H. & Wanker, E. E. (1997). Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90, 549-58.
55. Scherzinger, E., Sittler, A., Schweiger, K., Heiser, V., Lurz, R., Hasenbank, R., Bates, G. P., Lehrach, H. & Wanker, E. E. (1999). Self-assembly of polyglutaminecontaining huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc Natl Acad Sci USA 96, 4604-9.
56. Onodera, O., Burke, J. R., Miller, S. E., Hester, S., Tsuji, S., Roses, A. D. & Strittmatter, W. J. (1997). Oligomerization of expandedpolyglutamine domain fluorescent fusion proteins in cultured mammalian cells. Biochem Biophys Res Commun 238, 599-605.
57. Perez, M. K., Paulson, H. L., Pendse, S. J., Saionz, S. J., Bonini, N. M. & Pittman, R. N. (1998). Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J Cell Biol 143, 1457-70.
58. Sherman, M. Y. & Muchowski, P. J. (2003). Making yeast tremble: yeast models as tools to study neurodegenerative disorders. Neuromolecular Med 4, 133-46.
59. Driscoll, M. & Gerstbrein, B. (2003). Dying for a cause: invertebrate genetics takes on human neurodegeneration. Nat Rev Genet 4, 181-94.
60. Kazantsev, A., Preisinger, E., Dranovsky, A., Goldgaber, D. & Housman, D. (1999). Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc Natl Acad Sci USA 96, 11404-9.
61. Huang, C. C., Faber, P. W., Persichetti, F., Mittal, V., Vonsattel, J. P., MacDonald, M. E. & Gusella, J. F. (1998). Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat Cell Mol Genet 24, 217-33.
62. Preisinger, E., Jordan, B. M., Kazantsev, A. & Housman, D. (1999). Evidence for a recruitment and sequestration mechanism in Huntington's disease. Philos Trans R Soc Lond B Biol Sci 354, 1029-34.
63. McCampbell, A., Taylor, J. P., Taye, A. A., Robitschek, J., Li, M., Walcott, J., Merry, D., Chai, Y., Paulson, H., Sobue, G. & Fischbeck, K. H. (2000). CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet 9, 2197-202.
64. Howlett, D. R., Jennings, K. H., Lee, D. C., Clark, M. S., Brown, F., Wetzel, R., Wood, S. J., Camilleri, P. & Roberts, G. W. (1995). Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration 4, 23-32.
65. Wood, S. J., Chan, W. & Wetzel, R. (1996). Seeding of Ab fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochem. 35, 12623-12628.
66. Chen, S., Berthelier, V., Hamilton, J. B., O'Nuallain, B. & Wetzel, R. (2002). Amyloid-like features of polyglutamine aggregates and their assembly kinetics. Biochemistry 41, 7391-7399.
67. Berthelier, V., Hamilton, J. B., Chen, S. & Wetzel, R. (2001). A microtiter plate assay for polyglutamine aggregate extension. Anal Biochem 295, 227-36.
68. Zagorski, M. G., Yang, J., Shao, H., Ma, K., Zeng, H. & Hong, A. (1999). Methodological and chemical factors affecting amyloid-b amyloidogenicity. Meth Enzymol 309, 189-204.
69. Franks, F. (1985). Biophysics and biochemistry at low temperatures, Cambridge University Press, Cambridge.
70. Franks, F. (1993). Storage stabilization of proteins. In Protein Biotechnology: Isolation, Characterization and Stabilization (Franks, F., ed.), pp. 489-531. Humana Press, New York.
71. Jaenicke, R. & Seckler, R. (1997). Protein Assembly In Vitro. In Protein Misassembly (Wetzel, R., ed.), Vol. 50, pp. 1-59. Academic Press, San Diego.
72. Anderson, V. J. & Lekkerkerker, H. N. (2002). Insights into phase transition kinetics from colloid science. Nature 416, 811-5.
73. Bishop, M. F. & Ferrone, F. A. (1984). Kinetics of nucleationcontrolled polymerization. A perturbation treatment for use with a secondary pathway. Biophys J 46, 631-44.
74. Ferrone, F. (1999). Analysis of protein aggregation kinetics. Meths. Enzymol. 309, 256-274.
75. Cao, Z. & Ferrone, F. A. (1996). A 50th order reaction predicted and observed for sickle hemoglobin nucleation. J Mol Biol 256, 219-22.
76. Chen, S., Ferrone, F. & Wetzel, R. (2002). Huntington's Disease age-ofonset linked to polyglutamine aggregation nucleation. Proc. Natl. Acad. Sci. USA 99, 11884-11889.
77. Abraham, F. F. (1974). Homogeneous Nucleation Theory, Academic Press, New York.
78. Perutz, M. F. & Windle, A. H. (2001). Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats. Nature 412, 143-4.
79. Serio, T. R., Cashikar, A. G., Kowal, A. S., Sawicki, G. J., Moslehi, J. J., Serpell, L., Arnsdorf, M. F. & Lindquist, S. L. (2000). Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science 289, 1317-21.
80. Naiki, H. & Gejyo, F. (1999). Kinetic analysis of amyloid fibril formation. Meths Enzymol 309, 305-318.
81. Esler, W. P., Stimson, E. R., Ghilardi, J. R., Felix, A. M., Lu, Y. A., Vinters, H. V., Mantyh, P. W. & Maggio, J. E. (1997). A beta deposition inhibitor screen using synthetic amyloid. Nat Biotechnol 15, 258-63.
82. Myszka, D. G., Wood, S. J. & Biere, A. L. (1999). Analysis of fibril elongation using surface plasmon resonance biosensors. In Amyloid, Prions and other Protein Aggregates (Wetzel, R., ed.), Vol. 309, pp. 386-402. Academic Press, San Diego.
83. Berthelier, V. & Wetzel, R. (2003). An assay for characterizing the in vitro kinetics of polyglutamine aggregation. In Methods in Molecular Medicine: Neurogenetics (N. T. Potter, e., ed.), pp. 295-303. Humana Press, New York.
84. Esler, W. P., Stimson, E. R., Jennings, J. M., Vinters, H. V., Ghilardi, J. R., Lee, J. P., Mantyh, P. W. & Maggio, J. E. (2000). Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. Biochemistry 39, 6288-95.
85. Nucifora, F. C., Jr., Sasaki, M., Peters, M. F., Huang, H., Cooper, J. K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V. L., Dawson, T. M. & Ross, C. A. (2001). Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291, 2423-8.
86. Harper, J. D., Wong, S. S., Lieber, C. M. & Lansbury, P. T. (1997). Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol 4, 119-25.
87. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W. & Glabe, C. G. (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-9.
88. Poirier, M. A., Li, H., Macosko, J., Cai, S., Amzel, M. & Ross, C. A. (2002). Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J Biol Chem 277, 41032-7.
89. Divry, P. & Florkin, M. (1927). Sur les proprietes optiques de l'amyloide. C. R. Seances Soc Biol 97, 1808-10.
90. Westermark, G. T., Johnson, K. H. & Westermark, P. (1999). Staining methods for identification of amyloid in tissue. Methods Enzymol 309, 3-25.
91. Klunk, W. E., Jacob, R. F. & Mason, R. P. (1999). Quantifying amyloid beta-peptide (Abeta) aggregation using the congo red-abeta (CR-abeta) spectrophotometric assay [In Process Citation]. Anal Biochem 266, 66-76.
92. Naiki, H., Higuchi, K., Hosokawa, M. & Takeda, T. (1989). Fluorometric determination of amyloid fibrils in vitro using the fluorscent dye, thioflavine T. Anal. Biochem. 177, 244-249.
93. LeVine, H. (1999). Quantification of b-sheet amyloid fibril structures with thioflavin T. Meth Enzymol 309, 274-84.
94. Woody, R. W. (1996). Theory of circular dichroism of proteins. In Circular Dichroism and Conformational Analysis of Biomolecules (Fasman, G. D., ed.), pp. 25-67. Plenum, New York.
95. Hrncic, R., Wall, J., Wolfenbarger, D. A., Murphy, C. L., Schell, M., Weiss, D. T. & Solomon, A. (2000). Antibody-Mediated Resolution of Light Chain-Associated Amyloid Deposits. Am J Pathol 157, 1239-1246.
96. O'Nuallain, B. & Wetzel, R. (2002). Conformational antibodies recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci USA 99, 1485-1490.
97. Sunde, M. & Blake, C. (1997). The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv Protein Chem 50, 123-159.
98. Wood, S. J., Wetzel, R., Martin, J. D. & Hurle, M. R. (1995). Prolines and amyloidogenicity in fragments of the Alzheimer's peptide b/A4. Biochem. 34, 724-730.
99. Williams, A., Portelius, E., Kheterpal, I., Guo, J., Cook, K., Xu, Y. & Wetzel, R. (2004). Mapping Ab amyloid fibril secondary structure using scanning proline mutagenesis. J. Mol. Biol., 335, 833-42.
100. Venkatraman, J., Shankaramma, S. C. & Balaram, P. (2001). Design of folded peptides. Chem Rev 101, 3131-52.
101. Wetzel, R. (2002). Ideas of order for amyloid fibril structure. Structure 10, 1031-1036.
102. Starikov, E. B., Lehrach, H. & Wanker, E. E. (1999). Folding of oligoglutamines: a theoretical approach based upon thermodynamics and molecular mechanics. J Biomol Struct Dyn 17, 409-27.
103. Perutz, M. F., Finch, J. T., Berriman, J. & Lesk, A. (2002). Amyloid fibers are water-filled nanotubes. Proc Natl Acad Sci USA 99, 5591-5.
104. Jenkins, J. & Pickersgill, R. (2001). The architecture of parallel betahelices and related folds. Prog Biophys Mol Biol 77, 111-75.
105. Pickersgill, R. W. (2003). A primordial structure underlying amyloid. Structure (Camb) 11, 137-8.
106. Bence, N. F., Sampat, R. M. & Kopito, R. R. (2001). Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552-5.
107. Kopito, R. R. (2000). Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 10, 524-30.
108. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T. & Lansbury, P. T., Jr. (2002). Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291.
109. Margolis, R. L., Abraham, M. R., Gatchell, S. B., Li, S. H., Kidwai, A. S., Breschel, T. S., Stine, O. C., Callahan, C., McInnis, M. G. & Ross, C. A. (1997). cDNAs with long CAG trinucleotide repeats from human brain. Hum Genet 100, 114-22.
110. Hancock, J. M., Worthey, E. A. & Santibanez-Koref, M. F. (2001). A role for selection in regulating the evolutionary emergence of diseasecausing and other coding CAG repeats in humans and mice. Mol Biol Evol 18, 1014-23.
111. Collins, J. R., Stephens, R. M., Gold, B., Long, B., Dean, M. & Burt, S. K. (2003). An exhaustive DNA micro-satellite map of the human genome using high performance computing. Genomics 82, 10-9.
112. Talcott, B. & Moore, M. S. (1999). Getting across the nuclear pore complex. Trends Cell Biol 9, 312-8.
113. Osmand, A. P., Berthelier, V. & Wetzel, R. (2002). Identification of aggregation foci, intracellular neuronal structures in the neocortex in Huntington's disease capable of recruiting polyglutamine. Program 293.6, 2002 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2002. Online.
114. Heiser, V., Scherzinger, E., Boeddrich, A., Nordhoff, E., Lurz, R., Schugardt, N., Lehrach, H. & Wanker, E. E. (2000). Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: Implications for Huntington's disease therapy. Proc. Natl. Acad. Sci. (USA) 97, 6739-6744.
115. Wetzel, R., Ed. (1999). Amyloid, Prions, and other Protein Aggregates. Methods in Enzymology. Edited by Abelson, J. N. & Simon, M. I. San Diego, CA: Academic Press.
116. Kheterpal, I., Zhou, S., Cook, K. D. & Wetzel, R. (2000). Abeta amyloid fibrils possess a core structure highly resistant to hydrogen exchange. Proc Natl Acad Sci USA 97, 13597-601.
117. Kheterpal, I., Williams, A., Murphy, C., Bledsoe, B. & Wetzel, R. (2001). Structural features of the Ab amyloid fibril elucidated by limited proteolysis. Biochem. 40, 11757-11767.
118. Torok, M., Milton, S., Kayed, R., Wu, P., McIntire, T., Glabe, C. G. & Langen, R. (2002). Structural and Dynamic Features of Alzheimer's Abeta Peptide in Amyloid Fibrils Studied by Site-directed Spin Labeling. J Biol Chem 277, 40810-40815.
119. Petkova, A. T., Ishii, Y., Balbach, J. J., Antzutkin, O. N., Leapman, R. D., Delaglio, F. & Tycko, R. (2002). A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA 99, 16742-7.
120. Foguel, D., Suarez, M. C., Ferrao-Gonzales, A. D., Porto, T. C., Palmieri, L., Einsiedler, C. M., Andrade, L. R., Lashuel, H. A., Lansbury, P. T., Kelly, J. W. & Silva, J. L. (2003). Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities. Proc Natl Acad Sci USA 100, 9831-6.